| Name | Title | Contact Details |
|---|
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.
Salina Regional Health Center offers rehabilitation services to a wide array of patients. We provide Physical Therapy, Occupational Therapy, Recreational Therapy, Speech Therapy, and Rehabilitation Nursing to many ages.
Tech-Pro Medical Systems is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2012 by international bestselling authors, work-life balance experts, and holistic healthcare providers, Dr. Dave Braun and Dr. Troy Amdahl, Oola provides a simple and easy-to-follow lifestyle framework designed to lead you, step by step, to a life of less stress, more personal growth, and a clearer path toward living your unique purpose. The concept originally ideated in 1997 as Dr. Braun and Dr. Amdahl worked to better themselves in the seven key areas of life -- Fitness, Finance, Family, Field (career), Faith, Friends, and Fun. Since then, the Oola lifestyle has become a global phenomenon, with over a million followers in 40 countries actively creating their best lives. In 2021, Oola announced an affordable personal development eLearning platform to add to their offerings. Expected to launch in Summer 2021, the new platform will accelerate Oola`s goal of impacting one billion lives in seven years.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.